Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma’s Olafsson Offers Latest On Advair And Vascepa Rivals

Among Four Key Aspects That Will Underpin US Generics Business In 2021

Executive Summary

Four key “moving pieces,” including the next developments for rivals to Advair and Vascepa, will influence the success of Hikma’s US generics business, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview.

You may also be interested in...



Hikma Set For Ryaltris Take Off As Glenmark Wins USFDA Nod

Glenmark is celebrating a “major milestone,” after its Ryaltris nasal spray to treat seasonal allergic rhinitis was approved by the FDA. Hikma will handle commercialization in the US, as part of its continued specialty push in the market.

Philip Morris Closes In On Vectura As £1.1bn Offer Passes Threshold

Philip Morris once again pledged to up R&D in Vectura after its £1.1bn takeover offer for the UK-based inhalation specialist became unconditional, following the tobacco giant’s acrimonious face-off with private equity Carlyle earlier this year.

Philip Morris Bid For Vectura Trumps Carlyle Takeover

Tobacco giant Philip Morris International has swept in with a superior offer for the UK’s Vectura group, outbidding Carlyle after its takeover attempt was announced in May. Vectura is recommending that its shareholders back the improved offer.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150733

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel